Investment analysis and risk management in pharmaceutical companies

Basit Öğe Kaydı
dc.contributor.authorOzyesil, Mustafa
dc.contributor.authorTembelo, Havane
dc.date.accessioned2026-01-31T15:09:03Z
dc.date.available2026-01-31T15:09:03Z
dc.date.issued2025
dc.departmentİstanbul Beykent Üniversitesi
dc.description.abstractBackground and Aims: The pharmaceutical industry, which is known for its high levels of innovation and substantial research and development efforts, is crucial for global healthcare advancement. Developing new drugs requires significant R&D investments, which involve high levels of uncertainty and high costs. This study analyzes the investment strategies and risk management practises of leading pharmaceutical companies, Pfizer and Novartis. Methods: Financial performance indicators, investment trends, and risk mitigation techniques for Pfizer and Novartis were examined. The analysis focused on how these companies balance innovation with mitigating risks through substantial R&D investments. Results: This study found that significant R&D investments drive revenue growth, profitability, and stock prices. Specifically, 67.7% of the variability in revenue, 70.9% of the variability in net profit margin, and 48.3% of the variability in stock price growth are attributed to R&D expenditures. Conclusion: These findings highlight the critical role of continuous innovation and strategic investment in maintaining a competitive advantage and financial health in the pharmaceutical industry. R&D investments are essential for driving revenue growth, enhancing profitability, and boosting stock prices, underscoring the need for strategic risk management practises.
dc.identifier.doi10.26650/IstanbulJPharm.2025.1491350
dc.identifier.endpage109
dc.identifier.issn2587-2087
dc.identifier.issue1
dc.identifier.startpage101
dc.identifier.trdizinid1334621
dc.identifier.urihttps://doi.org./10.26650/IstanbulJPharm.2025.1491350
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1334621
dc.identifier.urihttps://hdl.handle.net/20.500.12662/10797
dc.identifier.volume55
dc.identifier.wosWOS:001485691900013
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherIstanbul Univ, Fac Pharmacy
dc.relation.ispartofIstanbul Journal of Pharmacy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260128
dc.subjectPharmaceutical Industry
dc.subjectR&D Investment
dc.subjectFinancial Performance
dc.subjectRisk Management
dc.subjectInnovation
dc.titleInvestment analysis and risk management in pharmaceutical companies
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu